Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:46:20.952Z.
Calculation as of: 2026-10-06T15:46:20.952Z.
Quote observation: 2026-10-06T15:45:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3328ed161ff00c537a80d7dceb604f662f1c22c4e65cb57a824bf36ce3bbbe60
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Corvus Pharmaceuticals, Inc.
Market Cap
$892.19M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$901.76M
EBITDA Yield
16.62%
TTM Avg
17.01%
3Y Avg
17.01%
5Y Avg
17.01%
Market Cap
$865.07M
EBITDA Yield
N/A
TTM Avg
3.15%
3Y Avg
3.15%
5Y Avg
3.15%
Market Cap
$841.07M
EBITDA Yield
N/A
TTM Avg
5.29%
3Y Avg
9.22%
5Y Avg
17.53%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $892.19M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $897.66M | 9.46% | 10.83% | 7.54% | 6.58% |
| Arbutus Biopharma Corp (ABUS)vs › | $901.76M | 16.62% | 17.01% | 17.01% | 17.01% |
| HealthStream, Inc. (HSTM)vs › | $914.51M | 7.97% | 9.57% | 8.00% | 7.50% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $865.07M | N/A | 3.15% | 3.15% | 3.15% |
| CeriBell, Inc. (CBLL)vs › | $933.77M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $841.81M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $839.06M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $841.07M | N/A | 5.29% | 9.22% | 17.53% |
| Jade Biosciences, Inc. (JBIO)vs › | $836.04M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
